Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

NCT01268020 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
5
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Institute for Neurodegenerative Disorders